Reduction of bone cancer pain by activation of spinal cannabinoid receptor 1 and its expression in the superficial dorsal horn of the spinal cord in a murine model of bone cancer pain

Anesthesiology

Volumn 111, Issue 1, 2009, Pages 173-186

  Furuse, Shingo ^a   Kawamata, Tomoyuki ^a   Yamamoto, Jun ^a   Niiyama, Yukitoshi ^a   Omote, Keiichi ^b   Watanabe, Masahiko ^b   Namiki, Akiyoshi ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ARACHIDONYL 2 CHLOROETHYLAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; MICROTUBULE ASSOCIATED PROTEIN 2; MU OPIATE RECEPTOR; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; URB 602;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE CANCER; CANCER PAIN; CATALEPSY; CONTROLLED STUDY; DRUG EFFICACY; IMMUNOHISTOCHEMISTRY; MALE; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PRESYNAPTIC INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA CELL; SPINAL CORD DORSAL HORN; STATISTICAL ANALYSIS; WESTERN BLOTTING;

EID: 67650089752     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3181a51e0d     Document Type: Article

References (50)

1. Banning A, Sjogren P, Henriksen H: Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic. Pain 1991; 45:45-8
2. Portenoy RK: Pain and quality of life: Clinical issues and implications for research. Oncology 1990; 4:172-8
3. Portenoy RK, Lesage P: Management of cancer pain. Lancet 1999; 353:1695-700
4. Luger NM, Sabino MA, Schwei MJ, Mach DB, Pomonis JD, Keyser CP, Rathbun M, Clohisy DR, Honore P, Yaksh TL, Mantyh PW: Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer versus inflammatory pain. Pain 2002; 99:397-406
5. YamamotoJ, KawamataT, NiiyamaY, Omote K, Namiki A: Down-regulation of mu opioid receptor expression within distinct subpopulations of dorsal root ganglion neurons in a murine model of bone cancer pain. Neuroscience 2008;151:843-53
6. Freund TF, Katona I, Piomelli D: Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 2003; 83:1017-66
7. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB: Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996; 384:83-7
8. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D: Brain monoglyceride lipase participating in endocannabinoid inacti vation. Proc Natl Acad SciUSA 2002; 99:10819-24
9. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346:561-4
10. Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365:61-5
11. Farquhar-Smith WP, Egertova M, Bradbury EJ, McMahon SB, Rice AS,
12. Elphick MR: Cannabinoid CB(1) receptor expression in rat spinal cord. Mol Cell Neurosci 2000; 15:510-21
13. Brown AG: The dorsal horn of the spinal cord. Q J Exp Physiol 1982;67:193-212
14. Cervero F, Iggo A: The substantia gelatinosa of the spinal cord: A critical review. Brain 1980; 103:717-72
15. Morisset V, Urban L: Cannabinoid-induced presynaptic inhibition of glu-tamatergic EPSCs in substantia gelatinosa neurons of the rat spinal cord. J Neu- rophysiol 2001; 86:40-8
16. Kelly S, Chapman V: Selective cannabinoid CB1 receptor activation inhibits spinal nociceptive transmission in vivo. J Neurophysiol 2001; 86:3061-4
17. Sagar DR, Kelly S, Millns PJ, O'Shaughnessey CT, Kendall DA, Chapman V:Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. Eur J Neurosci 2005;22:371-9
18. Drew LJ, Harris J, Millns PJ, Kendall DA, Chapman V: Activation of spinal cannabinoid 1 receptors inhibits C-fibre driven hyperexcitable neuronal responses and increases [35S]GTPgammaS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats. Eur J Neurosci 2000; 12:2079-86
19. Rahn EJ, Makriyannis A, Hohmann AG: Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemothera-peutic agent vincristine in rats. Br J Pharmacol 2007; 152:765-77
20. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ,Rubino T, Michalski CW, Marsicano G, Monory K, Mackie K, Marian C, Batkai S, Parolaro D, Fischer MJ, Reeh P, Kunos G, Kress M, Lutz B, Woolf CJ, Kuner R:Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 2007; 10:870-9
21. Honore P, LugerNM, Sabino MA, Schwei MJ, Rogers SD, Mach DB, O'keefe PF, Ramnaraine ML, Clohisy DR, Mantyh PW: Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 2000; 6:521-8
22. Kawamata T, Omote K, Kawamata M, Iwasaki H, Namiki A: Antinociceptive interaction of intrathecal alpha2-adrenergic agonists, tizanidine and clonidine, with lidocaine in rats. ANESTHESIOLOGY 1997; 87:436-48
23. Niiyama Y, Kawamata T, Yamamoto J, Omote K, Namiki A: Bone cancer increases transient receptor potential vanilloid subfamily 1 expression within distinct subpopulations of dorsal root ganglion neurons. Neuroscience 2007;148:560-72
24. Sevcik MA, Ghilardi JR, Peters CM, Lindsay TH, Halvorson KG, Jonas BM, Kubota K, Kuskowski MA, Boustany L, Shelton DL, Mantyh PW: Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain 2005; 115:128-41
25. Kuschinsky K, Hornykiewicz O: Morphine catalepsy in the rat: Relation to striatal dopamine metabolism. Eur J Pharmacol 1972; 19:119-22
26. Yoon MH, Choi JI: Pharmacologic interaction between cannabinoid and either clonidine or neostigmine in the rat formalin test. A NESTHESIOLOGY 2003; 99:701-7
27. Kawamura Y, Fukaya M, Maejima T, Yoshida T, Miura E, Watanabe M, Ohno-Shosaku T, Kano M: The CB1 cannabinoid receptor is the major cannabi- noid receptor at excitatory presynaptic sites in the hippocampus and cerebellum. J Neurosci 2006; 26:2991-3001
28. Yoshida T, Fukaya M, Uchigashima M, Miura E, Kamiya H, Kano M, Watanabe M: Localization of diacylglycerol lipase-alpha around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1 receptor. J Neurosci 2006; 26:4740-51
29. Fukaya M, Watanabe M: Improved immunohistochemical detection of postsynaptically located PSD-95/SAP90 protein family by protease section pre- treatment: A study in the adult mouse brain. J Comp Neurol 2000; 426:572-86
30. Miura E, FukayaM, Sato T, Sugihara K, Asano M, YoshiokaK, Watanabe M: Expression and distribution of JNK/SAPK-associated scaffold protein JSAP1 in developing and adult mouse brain. J Neurochem 2006; 97:1431-46
31. Fukudome Y, Ohno-Shosaku T, Matsui M, Omori Y, Fukaya M, Tsubokawa H, Taketo MM, Watanabe M, Manabe T, Kano M: Two distinct classes of musca- rinic action on hippocampal inhibitory synapses: M2-mediated direct suppression and M1/M3-mediated indirect suppression through endocannabinoid signalling. Eur J Neurosci 2004; 19:2682-92
32. Neumann S, Braz JM, Skinner K, Llewellyn-Smith IJ, Basbaum AI: Innocuous, not noxious, input activates PKCgamma interneurons of the spinal dorsal horn via myelinated afferent fibers. J Neurosci 2008; 28:7936-44
33. ZylkaMJ, Rice FL, Anderson DJ: Topographically distinct epidermal noci-ceptive circuits revealed by axonal tracers targeted to Mrgprd. Neuron 2005;45:17-25
34. Hamamoto DT, Giridharagopalan S, Simone DA: Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor-evoked hyperalgesia. Eur J Pharmacol 2007; 558:73-87
35. Potenzieri C, Harding-Rose C, Simone DA: The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms. Brain Res 2008; 1215:69-75
36. Khasabova IA, Khasabov SG, Harding-Rose C, Coicou LG, Seybold BA, Lindberg AE, Steevens CD, Simone DA, Seybold VS: A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. J Neurosci 2008; 28:11141-52
37. Kehl LJ, Hamamoto DT, Wacnik PW, Croft DL, Norsted BD, Wilcox GL, Simone DA: A cannabinoid agonist differentially attenuates deep tissue hyperal- gesia in animal models of cancer and inflammatory muscle pain. Pain 2003;103:175-86
38. Hald A, Ding M, Egerod K, Hansen RR, Konradsen D, J0rgensen SG, Atalay B, Nasser A, Bjerrum OJ, Heegaard AM: Differential effects of repeated low dose treatment with the cannabinoid agonist WIN 55,212-2 in experimental models of bone cancer pain and neuropathic pain. Pharmacol Biochem Behav 2008; 91:38-46
39. Mercadanre S, Arcuri E: Breakthrough pain in cancer patients: Pathophys- iology and treatment. Cancer Treat Rev 1998; 24:425-32
40. Hillard CJ, Manna S, Greenberg MJ, DiCamelli R, Ross RA, Stevenson LA, Murphy V, Pertwee RG, Campbell WB: Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther 1999; 289:1427-33
41. Suplita RL 2nd, Gutierrez T, Fegley D, Piomelli D, Hohmann AG: Endo- cannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia. Neuropharmacology 2006; 50:372-9
42. Russo R, Loverme J, La Rana G, Compton TR, Parrott J, Duranti A, Tontini A, Mor M, Tarzia G, Calignano A, Piomelli D: The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3=-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther 2007; 322:236-42
43. Jhaveri MD, Richardson D, Kendall DA, Barrett DA, Chapman V: Analgesic effects offattyacid amide hydrolase inhibitionina rat model ofneuropathic pain. J Neurosci 2006; 26:13318-27
44. Romero-Sandoval A, Nutile-McMenemy N, DeLeo JA: Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury. ANESTHESIOLOGY2008; 108:722-34
45. ZhangJ, Hoffert C, Vu HK, Groblewski T, Ahmad S, O'Donnell D: Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 2003; 17:2750-4
46. Zwick M, Davis BM, Woodbury CJ, Burkett JN, Koerber HR, Simpson JF, Albers KM: Glial cell line-derived neurotrophic factor is a survival factor for isolectin B4-positive, but not vanilloid receptor 1-positive, neurons in the mouse. J Neurosci 2002; 22:4057-65
47. Guo A, Vulchanova L, Wang J, Li X, Elde R: Immunocytochemical localization of the vanilloid receptor 1 (VR1): Relationship to neuropeptides, the P2X3 purinoceptor and IB4 binding sites. Eur J Neurosci 1999; 11:946-58
48. Mach DB, Rogers SD, Sabino MC, Luger NM, Schwei MJ, Pomonis JD,Keyser CP, Clohisy DR, Adams DJ, O'Leary P, Mantyh PW: Origins of skeletal pain: Sensory and sympathetic innervation of the mouse femur. Neuroscience2002; 113:155-66
49. Lim G, Sung B, Ji RR, Mao J: Upregulation of spinal cannabinoid-1-recep- tors following nerve injury enhances the effects ofWin 55,212-2 on neuropathic pain behaviors in rats. Pain 2003; 105:275-83
50. Wang S, Lim G, Mao J, Sung B, Yang L, Mao J: Central glucocorticoid receptors regulate the upregulation of spinal cannabinoid-1 receptors after peripheral nerve injury in rats. Pain 2007; 131:96-105